Pharma Licensing Deals Getting Special FTC Scrutiny; Court Upholds “Defective” Rule
This article was originally published in The Pink Sheet Daily
Executive Summary
FTC can still require drug makers to report transactions in which they license a patent but retain manufacturing rights or co-commercialization rights.